Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics. (11th May 2020)

• Record Type: Journal Article
• Authors: Martin-Blondel, Guillaume; Ruiz, Stéphanie; Murris, Marlène; Faguer, Stanilas; Duhalde, Véronigue; Eyvrard, Frédéric; Izopet, Jacques; Mansuy, Jean-Michel; Rolland, Yves; Delavigne, Karen; Guimbaud, Rosine; Pugnet, Grégory; Conil, Jean-Marie; Georges, Bernard; Delobel, Pierre; Minville, Vincent; Silva Sifontes, Stein; Concordet, Didier; Gandia, Peggy
• Is Part Of: Clinical infectious diseases. Volume 71:Number 11(2020)
• Page Start: 2962
• Page End: 2964
• Publication Date: 2020-05-11
• Subjects: COVID-19 -- hydroxychloroquine -- drug monitoring -- population pharmacokinetic modeling -- dosage regimens; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa558
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Different dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.